dromlakhani Avoid bisphosphonates, denosumab, testosterone, and leptin for BMD improvement in FHA
STEP 1 — Gather Information for bone health'.
Avoid bisphosphonates, denosumab, testosterone, and leptin for BMD improvement in FHA
STEP 1 — Gather Information
Confirm FHA diagnosis (exclude pregnancy, thyroid disease, hyperprolactinemia, anatomic outflow tract anomalies); obtain baseline lumbar spine or hip BMD Z-score by DXA; document duration of amenorrhea, weight, BMI, exercise intensity, nutritional intake, and psychological stressors.
STEP 2 — Rule In / Rule Out
If FHA is confirmed after excluding organic causes of amenorrhea, proceed to assess BMD; otherwise, stop and evaluate alternative diagnoses.
STEP 3 — Classify or Stratify
Classify BMD status: Z-score > -1.0 (normal to low-normal) versus Z-score ≤ -1.0 (low BMD) or presence of a fragility fracture.
STEP 4 — Decide
If Z-score ≤ -1.0 or a fragility fracture is present, recommend against bisphosphonates, denosumab, testosterone, or leptin; instead, initiate multidisciplinary therapy to correct energy imbalance (nutritional rehabilitation, cognitive behavioral therapy, exercise modification).
Clinical Guardrails / Mimics / Pitfalls
Do not prescribe bisphosphonates, denosumab, testosterone, or leptin solely for BMD improvement in FHA due to lack of efficacy and potential fetal teratogenicity; avoid using oral contraceptive pills as the sole strategy for bone health; do not overlook persistent energy deficit as the primary driver of bone loss; monitor for stress fractures despite pharmacologic avoidance; consider that leptin administration may cause weight loss and worsen energy imbalance.
Concrete Clinical Example
A 16‑year‑old female runner presents with 9 months of amenorrhea, BMI 16.8 kg/m2, lumbar spine Z‑score –1.8, and asks about denosumab for low BMD. After confirming FHA and excluding secondary causes, the clinician advises against denosumab and initiates a plan for increased caloric intake, weekly CBT, and reduced training volume.
Source: Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-00131